Expression of the IFNAR1 chain of type 1 interferon receptor in benign cells protects against progression of acute leukemia

References

• Kujawski LA, Talpaz M. The role of interferon-alpha in the treatment of chronic myeloid leukemia. Cytokine Growth Factor Rev. 2007;18:459–471.
   PubMed Web of Science ®Google Scholar
• Talpaz M, Mercer J, Hehlmann R. The interferon-alpha revival in CML. Ann Hematol. 2015;94:S195–S207.
   PubMed Web of Science ®Google Scholar
• Talpaz M, Hehlmann R, Quintas-Cardama A, et al. Re-emergence of interferon-α in the treatment of chronic myeloid leukemia. Leukemia. 2013;27:803–812.
   PubMed Web of Science ®Google Scholar
• Sumi M, Sato K, Kaiume H, et al. Second cord blood transplantation and interferon-alpha maintenance therapy for relapsed Ph + acute lymphoblastic leukemia with the T315I mutation. Leuk Lymphoma. 2016;58:1–3.
   Web of Science ®Google Scholar
• Smits EL, Anguille S, Berneman ZN. Interferon α may be back on track to treat acute myeloid leukemia. Oncoimmunology. 2013;2:e23619.
   PubMed Web of Science ®Google Scholar
• Platanias LC. Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat Rev Immunol. 2005;5:375–386.
   PubMed Web of Science ®Google Scholar
• Fuchs SY. Hope and fear for interferon: the receptor-centric outlook on the future of interferon therapy. J Interferon Cytokine Res. 2013;33:211–225.
   PubMed Web of Science ®Google Scholar
• Huangfu WC, Fuchs SY. Ubiquitination-dependent regulation of signaling receptors in cancer. Genes Cancer. 2010;1:725–734.
   PubMedGoogle Scholar
• Liu J, Plotnikov A, Banerjee A, et al. Ligand-independent pathway that controls stability of interferon alpha receptor. Biochem Biophys Res Commun. 2008;367:388–393.
   PubMed Web of Science ®Google Scholar
• Huangfu WC, Qian J, Liu C, et al. Inflammatory signaling compromises cell responses to interferon alpha. Oncogene. 2012;31:161–172.
   PubMed Web of Science ®Google Scholar
• Fish EN, Platanias LC. Interferon receptor signaling in malignancy: a network of cellular pathways defining biological outcomes. Mol Cancer Res. 2014;12:1691–1703.
   PubMed Web of Science ®Google Scholar
• Katsoulidis E, Kaur S, Platanias LC. Deregulation of interferon signaling in malignant cells. Pharmaceuticals (Basel). 2010;3:406–418.
   PubMedGoogle Scholar
• Katsoulidis E, Li Y, Mears H, et al. The p38 mitogen-activated protein kinase pathway in interferon signal transduction. J Interferon Cytokine Res. 2005;25:749–756.
   PubMed Web of Science ®Google Scholar
• Parker BS, Rautela J, Hertzog PJ. Antitumour actions of interferons: implications for cancer therapy. Nat Rev Cancer. 2016;16:131–144.
   PubMed Web of Science ®Google Scholar
• Zitvogel L, Galluzzi L, Kepp O, et al. Type I interferons in anticancer immunity. Nat Rev Immunol. 2015;15:405–414.
   PubMed Web of Science ®Google Scholar
• Katlinskaya YV, Katlinski KV, Yu Q, et al. Suppression of type I interferon signaling overcomes oncogene-induced senescence and mediates melanoma development and progression. Cell Rep. 2016;15:171–180.
   PubMed Web of Science ®Google Scholar
• DeKelver RC, Lewin B, Weng S, et al. RUNX1-ETO induces a type I interferon response which negatively effects t(8;21)-induced increased self-renewal and leukemia development. Leuk Lymphoma. 2014;55:884–891.
   PubMed Web of Science ®Google Scholar
• Mizutani T, Neugebauer N, Putz EM, et al. Conditional IFNAR1 ablation reveals distinct requirements of type I IFN signaling for NK cell maturation and tumor surveillance. Oncoimmunology. 2012;1:1027–1037.
   PubMed Web of Science ®Google Scholar
• Bhattacharya S, HuangFu WC, Dong G, et al. Anti-tumorigenic effects of type 1 interferon are subdued by integrated stress responses. Oncogene. 2013;32:4214–4221.
   PubMed Web of Science ®Google Scholar
• Katlinski KV, Gui J, Katlinskaya YV, et al. Inactivation of interferon receptor promotes the establishment of immune privileged tumor microenvironment. Cancer Cell. 2017;31:194–207.
   PubMed Web of Science ®Google Scholar
• Bhattacharya S, Zheng H, Tzimas C, et al. Bcr-abl signals to desensitize chronic myeloid leukemia cells to IFNα via accelerating the degradation of its receptor. Blood. 2011;118:4179–4187.
   PubMed Web of Science ®Google Scholar
• Bhattacharya S, Katlinski KV, Reichert M, et al. Triggering ubiquitination of IFNAR1 protects tissues from inflammatory injury. EMBO Mol Med. 2014;6:384–397.
   PubMed Web of Science ®Google Scholar
• Liu J, HuangFu WC, Kumar KG, et al. Virus-induced unfolded protein response attenuates antiviral defenses via phosphorylation-dependent degradation of the type I interferon receptor. Cell Host Microbe. 2009;5:72–83.
   PubMed Web of Science ®Google Scholar
• Pear WS, Miller JP, Xu L, et al. Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow. Blood. 1998;92:3780–3792.
   PubMed Web of Science ®Google Scholar
• Wertheim JA, Perera SA, Hammer DA, et al. Localization of BCR-ABL to F-actin regulates cell adhesion but does not attenuate CML development. Blood. 2003;102:2220–2228.
   PubMed Web of Science ®Google Scholar
• He Y, Wertheim JA, Xu L, et al. The coiled-coil domain and Tyr177 of bcr are required to induce a murine chronic myelogenous leukemia-like disease by bcr/abl. Blood. 2002;99:2957–2968.
   PubMed Web of Science ®Google Scholar
• Zhang X, Wong R, Hao SX, et al. The SH2 domain of bcr-Abl is not required to induce a murine myeloproliferative disease; however, SH2 signaling influences disease latency and phenotype. Blood. 2001;97:277–287.
   PubMed Web of Science ®Google Scholar
• Stoiber D, Kovacic B, Schuster C, et al. TYK2 is a key regulator of the surveillance of B lymphoid tumors. J Clin Invest. 2004;114:1650–1658.
   PubMed Web of Science ®Google Scholar
• Zheng H, Qian J, Baker DP, et al. Tyrosine phosphorylation of protein kinase D2 mediates ligand-inducible elimination of the type 1 interferon receptor. J Biol Chem. 2011;286:35733–35741.
   PubMed Web of Science ®Google Scholar
• Zheng H, Qian J, Varghese B, et al. Ligand-stimulated downregulation of the alpha interferon receptor: role of protein kinase D2. Mol Cell Biol. 2011;31:710–720.
   PubMed Web of Science ®Google Scholar
• Liu J, Carvalho LP, Bhattacharya S, et al. Mammalian casein kinase 1alpha and its leishmanial ortholog regulate stability of IFNAR1 and type I interferon signaling. Mol Cell Biol. 2009;29:6401–6412.
   PubMed Web of Science ®Google Scholar
• Katlinskaya YV, Katlinski KV, Lasri A, et al. Type I interferons control proliferation and function of the intestinal epithelium. Mol Cell Biol. 2016;36:1124–1135.
   PubMed Web of Science ®Google Scholar
• Schneider RK, Adema V, Heckl D, et al. Role of casein kinase 1A1 in the biology and targeted therapy of del(5q) MDS. Cancer Cell. 2014;26:509–520.
   PubMed Web of Science ®Google Scholar
• Jaras M, Miller PG, Chu LP, et al. Csnk1a1 inhibition has p53-dependent therapeutic efficacy in acute myeloid leukemia. J Exp Med. 2014;211:605–612.
   PubMed Web of Science ®Google Scholar
• Kronke J, Fink EC, Hollenbach PW, et al. Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS. Nature. 2015;523:183–188.
   PubMed Web of Science ®Google Scholar
• Bhattacharya S, HuangFu WC, Liu J, et al. Inducible priming phosphorylation promotes ligand-independent degradation of the IFNAR1 chain of type I interferon receptor. J Biol Chem. 2010;285:2318–2325.
   PubMed Web of Science ®Google Scholar
• Bhattacharya S, Qian J, Tzimas C, et al. Role of p38 protein kinase in the ligand-independent ubiquitination and down-regulation of the IFNAR1 chain of type I interferon receptor. J Biol Chem. 2011;286:22069–22076.
   PubMed Web of Science ®Google Scholar
• Lalaoui N, Hanggi K, Brumatti G, et al. Targeting p38 or MK2 enhances the anti-leukemic activity of Smac-mimetics. Cancer Cell. 2016;29:145–158.
   PubMed Web of Science ®Google Scholar
• Beug ST, Tang VA, LaCasse EC, et al. Smac mimetics and innate immune stimuli synergize to promote tumor death. Nat Biotechnol. 2014;32:182–190.
   PubMed Web of Science ®Google Scholar